UroToday

ESMO 2025: Efficacy of Cabozantinib and Nivolumab in Cluster 1/2 Metastatic Clear Cell Renal Cell Carcinoma: Results from OPTIC RCC, a Phase II Trial of a Novel RNAseq-based ...

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress, held in Berlin, Germany, between October 17 th and 21 st, 2025, was host to a renal and urothelial carcinoma ...
UroToday

US Prostate Cancer Conferences

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

ESMO 2025: Neoadjuvant Darolutamide + ADT for High/very-High Risk Locally Advanced Prostate Cancer: A Multi-Center, Open Label, Single Arm, Phase 2 Trial

(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Kaiwei Yang discussing a phase 2 trial assessing neoadjuvant darolutamide + ADT for ...
UroToday

Non-Muscle Invasive Bladder Cancer

ESMO 2024, High and Intermediate Risk Non Muscle Invasive Bladder Cancer (HMR-NMIBC), Trifunctional Anti-EpCAM/CD3 bsAb Catumaxomab Intravesically, catumaxomab (CAT), EpCAM+ tumor cells.
UroToday

EAU 2021: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer: Outcomes in High-Volume and Low-Volume Disease From the TITAN Final Analysis

(UroToday.com) At the metastatic prostate cancer session at the European Association of Urology 2021 Virtual Meeting, Dr. Simon Chowdhury presented results of outcomes in high and low-volume disease ...
UroToday

The Latest Peyronie's Disease Research

Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...
UroToday

ESMO 2025: Phase III Trial of [177Lu]Lu-PSMA-617 Combined with ADT + ARPI in Patients with PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer (PSMAddition)

ESMO 2025, PSMA-positive metastatic hormone-sensitive prostate cancer, [177Lu]Lu-PSMA-617, VISION trial, PSMAfore trial, PSMAddition trial, 68Ga-PSMA-11 PET/CT.
UroToday

The Latest Research in Pelvic Prolapse

The Kurt extraperitoneal ligamentopexy: A new surgical method with uterine preservation for pelvic organ prolapse, "Beyond the Abstract," by Sefa Kurt and Mehmet Tunc Canda ...
UroToday

AUA 2022: AUA Guidelines: Localized Prostate Cancer

Clinicians should use clinical T stage, serum prostate-specific antigen (PSA), Grade Group (Gleason score), and tumor volume on biopsy to risk stratify patients with newly diagnosed prostate cancer.
UroToday

ESMO 2019: GALAHAD - A Phase 2 Study of Niraparib in Patients with mCRPC and Biallelic DNA-Repair Gene Defects, A Pre-Specified Interim Analysis

Barcelona, Spain (UroToday.com) Patients with metastatic castration-resistant prostate cancer (mCRPC) and disease progression after androgen receptor (AR) targeted therapy and taxane-based ...
UroToday

ESMO 2023: Phase 1/2 Study of Bavdegalutamide, a PROTAC Androgen Receptor Degrader, in mCRPC: Radiographic Progression-Free Survival in Patients with AR Ligand-Binding Domain ...

(UroToday.com) The 2023 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Daniel Petrylak discussing radiographic progression-free survival (rPFS) in patients ...
UroToday

ESMO 2025: A Phase III Study of Capivasertib + Abiraterone versus Placebo + Abiraterone in Patients with PTEN-deficient De Novo Metastatic Hormone-sensitive Prostate Cancer ...

ESMO 2025, de novo Metastatic Hormone-sensitive Prostate Cancer (mHSPC), capivasertib + abiraterone, CAPItello-281 trial, capivasertib.